Moomoo AI 已提取核心信息
Bristol-Myers Squibb (BMY) has successfully completed its tender offer to acquire all outstanding shares of RayzeBio, Inc. for $62.50 per share in cash, amounting to approximately $4.1 billion. The offer, which expired on February 22, 2024, saw approximately 86% of RayzeBio's shares being validly tendered and not withdrawn. With the minimum condition for the tender offer satisfied, Bristol-Myers Squibb plans to promptly accept for payment all validly tendered shares on February 26, 2024. The acquisition will result in RayzeBio becoming a wholly owned subsidiary of Bristol-Myers Squibb, and its shares will be delisted from the Nasdaq Global Market. The merger is expected to be completed on the same day as the acceptance of the shares, without the need for a vote from RayzeBio's stockholders. Following the merger, Bristol-Myers Squibb intends to terminate the registration of RayzeBio's shares under the Exchange Act and suspend all of its reporting obligations as soon as practicable.
Bristol-Myers Squibb (BMY) has successfully completed its tender offer to acquire all outstanding shares of RayzeBio, Inc. for $62.50 per share in cash, amounting to approximately $4.1 billion. The offer, which expired on February 22, 2024, saw approximately 86% of RayzeBio's shares being validly tendered and not withdrawn. With the minimum condition for the tender offer satisfied, Bristol-Myers Squibb plans to promptly accept for payment all validly tendered shares on February 26, 2024. The acquisition will result in RayzeBio becoming a wholly owned subsidiary of Bristol-Myers Squibb, and its shares will be delisted from the Nasdaq Global Market. The merger is expected to be completed on the same day as the acceptance of the shares, without the need for a vote from RayzeBio's stockholders. Following the merger, Bristol-Myers Squibb intends to terminate the registration of RayzeBio's shares under the Exchange Act and suspend all of its reporting obligations as soon as practicable.
百时美施贵宝（BMY）成功完成了以每股62.50美元现金收购RayzeBio, Inc.所有已发行股份的要约，总额约为41亿美元。该要约于2024年2月22日到期，RayzeBio约有86％的股票进行了有效投标且未撤回。在满足要约的最低条件后，百时美施贵宝计划在2024年2月26日立即接受所有有效投标的股票付款。此次收购将使RayzeBio成为百时美施贵宝的全资子公司，其股票将从纳斯达克全球市场退市。合并预计将在接受股票的同一天完成，无需RayzeBio的股东投票。合并后，百时美施贵宝打算终止RayzeBio根据《交易法》注册的股份，并尽快暂停其所有报告义务。
百时美施贵宝（BMY）成功完成了以每股62.50美元现金收购RayzeBio, Inc.所有已发行股份的要约，总额约为41亿美元。该要约于2024年2月22日到期，RayzeBio约有86％的股票进行了有效投标且未撤回。在满足要约的最低条件后，百时美施贵宝计划在2024年2月26日立即接受所有有效投标的股票付款。此次收购将使RayzeBio成为百时美施贵宝的全资子公司，其股票将从纳斯达克全球市场退市。合并预计将在接受股票的同一天完成，无需RayzeBio的股东投票。合并后，百时美施贵宝打算终止RayzeBio根据《交易法》注册的股份，并尽快暂停其所有报告义务。
有用
没用